CD19 and diffuse large B-cell lymphoma: A similar clinical trial for relapsed/refractory DLBCL is to use CD19-CAR-T cells with IL-7 and CCL19 co-expression in combination with an anti-PD1 monoclonal antibody (NCT04381741).